Bear,

I am not arguing with your statements, but I am trying to put a different slant on this discussion, possibly not sucessfully.

My point, if I have got it right, is that I believe RVX has a patent and can market Apabetalone with rosuvastatin, which is essentially Crestor that has come off patent protection.  RVX could market a new improved statin using rosuvastin + Apabetalone.  I was under the impression that statins were used essentially to reduce MACE events.  Adding Apabetalone seems to reduce inflamation that leads to artery build up.  ie - a new improved statin for market domination.

At the AGM, Don was whining about educating the world to epigentics.  Could he not market a new improved rouvastatin (statin) with Apabetalone for added efficacy.  People understand statins, and Don would not even have to mention the word epigentics in marketing presentions.

Waiting to be corrected.

JMO

Absolutely